RDNT vs. CSTL, BDSX, PSNL, LH, DGX, NTRA, EXAS, GH, FTRE, and VCYT
Should you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Castle Biosciences (CSTL), Biodesix (BDSX), Personalis (PSNL), Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Exact Sciences (EXAS), Guardant Health (GH), Fortrea (FTRE), and Veracyte (VCYT). These companies are all part of the "medical laboratories" industry.
RadNet (NASDAQ:RDNT) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
77.9% of RadNet shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 5.1% of RadNet shares are owned by insiders. Comparatively, 7.2% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
RadNet has a net margin of 1.28% compared to Castle Biosciences' net margin of -12.28%. RadNet's return on equity of 5.05% beat Castle Biosciences' return on equity.
RadNet presently has a consensus target price of $64.00, suggesting a potential upside of 3.26%. Castle Biosciences has a consensus target price of $31.00, suggesting a potential upside of 47.20%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than RadNet.
RadNet has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.
RadNet received 261 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 65.71% of users gave RadNet an outperform vote while only 62.60% of users gave Castle Biosciences an outperform vote.
RadNet has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
In the previous week, Castle Biosciences had 2 more articles in the media than RadNet. MarketBeat recorded 10 mentions for Castle Biosciences and 8 mentions for RadNet. RadNet's average media sentiment score of 1.20 beat Castle Biosciences' score of 0.68 indicating that RadNet is being referred to more favorably in the media.
Summary
RadNet beats Castle Biosciences on 12 of the 18 factors compared between the two stocks.
Get RadNet News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
